Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F16%3A00462469" target="_blank" >RIV/67985823:_____/16:00462469 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/16:00060083 RIV/00216208:11130/16:10327758 RIV/00216208:11120/16:43911993 RIV/00064173:_____/16:N0000136

Výsledek na webu

<a href="http://dx.doi.org/10.1097/HJH.0000000000001029" target="_blank" >http://dx.doi.org/10.1097/HJH.0000000000001029</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/HJH.0000000000001029" target="_blank" >10.1097/HJH.0000000000001029</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Popis výsledku v původním jazyce

We evaluated the therapeutic effectiveness of a new, orally active epoxyeicosatrienoic acid analog (EET-A) in rats with angiotensin II (ANG II)-dependent malignant hypertension. Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C). EET-A treatment was started either simultaneously with I3C induction process or 10 days later during established hypertension. Blood pressure (BP), indices of renal and cardiac injury, and plasma and kidney levels of the components of the renin-angiotensin system (RAS) were determined. In I3C-induced hypertensive rats, early EET-A treatment attenuated BP increase (to 175  3 vs. 193  4 mmHg, on day 13), reduced albuminuria (15  1 vs. 28  2 mg/24 h), and cardiac hypertrophy as compared with untreated I3C-induced rats. This was associated with suppression of plasma and kidney ANG II levels and increases in plasma and kidney angiotensin (1-7) concentrations Remarkably, late EET-A treatment did not lower BP or improve renal and cardiac injury; indices of RAS activity were not affected. The new, orally active EET-A attenuated the development of experimental ANG II-dependent malignant hypertension, likely via suppression of the hypertensiogenic axis and augmentation of the vasodilatory/natriuretic axis of RAS.

Název v anglickém jazyce

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Popis výsledku anglicky

We evaluated the therapeutic effectiveness of a new, orally active epoxyeicosatrienoic acid analog (EET-A) in rats with angiotensin II (ANG II)-dependent malignant hypertension. Malignant hypertension was induced in Cyp1a1-Ren-2 transgenic rats by activation of the renin gene using indole-3-carbinol (I3C). EET-A treatment was started either simultaneously with I3C induction process or 10 days later during established hypertension. Blood pressure (BP), indices of renal and cardiac injury, and plasma and kidney levels of the components of the renin-angiotensin system (RAS) were determined. In I3C-induced hypertensive rats, early EET-A treatment attenuated BP increase (to 175  3 vs. 193  4 mmHg, on day 13), reduced albuminuria (15  1 vs. 28  2 mg/24 h), and cardiac hypertrophy as compared with untreated I3C-induced rats. This was associated with suppression of plasma and kidney ANG II levels and increases in plasma and kidney angiotensin (1-7) concentrations Remarkably, late EET-A treatment did not lower BP or improve renal and cardiac injury; indices of RAS activity were not affected. The new, orally active EET-A attenuated the development of experimental ANG II-dependent malignant hypertension, likely via suppression of the hypertensiogenic axis and augmentation of the vasodilatory/natriuretic axis of RAS.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/GA15-07544S" target="_blank" >GA15-07544S: Kardioprotektivní a antihypertenzní účinky agonistických analogů epoxyeikosatrienových kyselin.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Hypertension

ISSN

0263-6352

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

18

Strana od-do

2008-2025

Kód UT WoS článku

000384032800012

EID výsledku v databázi Scopus

2-s2.0-84978658313